A phase 1, open-label, randomized study comparing the immunogenicity and safety of various administration routes and doses of virosomal influenza vaccine in the elderly population

Trial Profile

A phase 1, open-label, randomized study comparing the immunogenicity and safety of various administration routes and doses of virosomal influenza vaccine in the elderly population

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Crucell Holland
  • Most Recent Events

    • 22 Nov 2016 New trial record
    • 10 Oct 2016 According to NanoPass Technologies media release, data will be presented at the World Vaccine Congress (WVC) 2016 in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top